AVI BioPharma

Weekly treatment with eteplirsen resulted in a 69.4-meter benefit on the 6-minute walk compared to placebo/delayed treatment; study extends earlier results showing eteplirsen caused dystrophin production

posted on July 24, 2012 - 10:55am
Editor's note (July 24, 2012): For a more in-depth discussion of the exon-skipping trial results, see A Closer Look: Extended Eteplirsen Treatment Benefits Walking in DMD.

Complete results of a U.K. trial of an exon-skipping drug in boys with DMD show drug is safe, increases dystrophin production

posted on July 26, 2011 - 11:24am
Complete and extremely encouraging findings from a phase 1b-2 trial of eteplirsen (AVI-4658), an exon skipping drug in development to treat a portion of the Duchenne muscular dystrophy (DMD) population, show the compound is safe and well-tolerated, and that it can significantly increase production of the needed dystrophin protein in recipients without eliciting an unwanted immune response.

Clinical trials of two different exon-skipping compounds show encouraging results; Duchenne MD participants are being sought for new trials

posted on March 29, 2011 - 11:42am
sClinical trials that use compounds called antisense oligonucleotides to cause skipping of exon 51 of the dystrophin gene in individuals with Duchenne muscular dystrophy (DMD) are moving forward in the United States and elsewhere. Exon skipping for DMD is a strategy that coaxes muscle fibers to ignore, or "skip," the genetic instructions for certain parts of the dystrophin gene so that functional...

Further analysis of data from a trial of the exon-skipping drug AVI4658 showed some participants had greatly increased dystrophin production

posted on June 2, 2010 - 10:15am
The biopharmaceutical company AVI BioPharma has announced additional encouraging results from its clinical trial of AVI4658, an experimental treatment for Duchenne muscular dystrophy (DMD). The new results show that, at higher doses, AVI4658 can result in substantial production of the needed dystrophin protein in muscle fibers. The company has not yet released results of any tests of muscle...

A trial of AVI4658, an experimental exon skipping construct for DMD, resulted in dystrophin production and appears safe

posted on April 15, 2010 - 3:57pm
AVI4658, an experimental treatment for patients with Duchenne muscular dystrophy (DMD) caused by certain mutations in the gene for the muscle protein dystrophin, has shown promising results when delivered intravenously to 19 trial participants.

Early results show that when AVI4658 is delivered system-wide through the bloodstreams of boys with DMD, it’s safe and increases dystrophin production.

posted on December 23, 2009 - 3:07pm
Interim results from a human clinical trial of the exon-skipping compound AVI4658 in boys with Duchenne muscular dystrophy (DMD) show that when the compound is delivered to the whole body via the bloodstream — rather than simply injected into a foot muscle as in a previous trial — it appears safe and leads to production of the missing muscle protein dystrophin.
posted on July 1, 2009 - 4:14pm
QUEST Vol. 16, No. 3
The following article contains items about: Duchenne and limb-girdle muscular dystrophies
posted on April 1, 2009 - 4:12pm
QUEST Vol. 16, No. 2
This article contains items about: Duchenne muscular dystrophy and spinal muscular atrophy